rGHRH(1-29)NH2

rGHRH(1-29)NH2, or recombinant Growth Hormone-Releasing Hormone (1-29) amide, is a synthetic peptide fragment representing the biologically active N-terminal sequence of human GHRH. As a potent agonist of the growth hormone-releasing hormone receptor, it plays a pivotal role in stimulating the synthesis and secretion of growth hormone from the anterior pituitary. The amide modification at the C-terminus enhances its stability and bioactivity, making it a valuable tool in peptide research and endocrine signaling studies. Its well-characterized sequence and receptor specificity render it a preferred model for investigating peptide-receptor interactions, signal transduction mechanisms, and the regulatory pathways governing growth hormone dynamics.

Peptide receptor studies: rGHRH(1-29)NH2 is widely employed in the investigation of GHRH receptor pharmacology and signaling. By serving as a selective agonist, it enables researchers to characterize receptor binding affinities, downstream signaling cascades, and the structural determinants of ligand-receptor specificity. These studies are critical for elucidating the molecular basis of peptide hormone action and contribute to the broader understanding of G protein-coupled receptor (GPCR) function in the endocrine system.

Endocrine regulation research: The peptide provides a robust model for exploring the regulatory mechanisms of growth hormone secretion in vitro. Utilizing rGHRH(1-29)NH2 in cultured pituitary cell systems allows for precise dissection of the pathways involved in hormone synthesis, release, and feedback inhibition. Such research supports the development of new hypotheses regarding the integration of hypothalamic signals and pituitary responses, offering insight into the complex homeostatic control of growth and metabolism.

Peptide stability and structure-activity relationship analysis: The amide-capped structure of rGHRH(1-29)NH2 is particularly advantageous for studies focused on peptide stability, degradation kinetics, and resistance to proteolytic cleavage. Researchers leverage this property to investigate structure-activity relationships, comparing the biological activity of various GHRH analogs and modified peptides. These analyses inform the design of novel peptide ligands with enhanced stability, receptor selectivity, or altered pharmacodynamic profiles.

Signal transduction pathway elucidation: By stimulating pituitary or heterologous cell lines expressing the GHRH receptor, rGHRH(1-29)NH2 is instrumental in mapping the intracellular signaling events triggered by GHRH receptor activation. Researchers can assess the activation of adenylate cyclase, cyclic AMP accumulation, and downstream kinase cascades, thereby delineating the molecular framework through which peptide hormones exert their effects on target cells.

Peptide synthesis and assay standardization: The well-defined sequence and biological activity of rGHRH(1-29)NH2 make it a valuable standard for peptide synthesis validation and bioassay calibration. Laboratories utilize this peptide to benchmark synthetic protocols, assess peptide purity, and calibrate bioassays measuring growth hormone-releasing activity. Its consistent performance supports reproducibility and comparability across research studies, contributing to the reliability of experimental outcomes in peptide-based investigations.

1. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

2. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

3. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

4. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

5. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines